

RSV vaccines – ACIP recommends expanded use in 50 – 59 years of age

- On April 16, 2025, the Centers for Disease Control and Prevention's (CDC) [Advisory Committee on Immunization Practices \(ACIP\)](#) voted 14 to zero with one abstention that adults 50 – 59 years of age who are at increased risk of severe respiratory syncytial virus (RSV) disease receive a single dose of RSV vaccine.
 - CDC will publish Clinical Considerations that describe chronic medical conditions and other risk factors for severe RSV disease for use in this risk-based recommendation.
 - RSV vaccination is recommended as a single dose only. Persons who have already received RSV vaccination are NOT recommended to receive another dose.
- This expands on ACIP's previous vote in June 2024 to recommend [RSV vaccines](#) for adults aged 60 – 74 years who are at increased risk and all adults aged 75 and older.
- The vaccines included in this expanded recommendation are Pfizer's [Abrysvo[®] \(RSV vaccine\)](#) and GSK's [Arexvy[®] \(RSV vaccine recombinant, adjuvanted\)](#).
- Moderna's [mRESVIA[®] \(RSV vaccine\)](#) is only approved for individuals 60 years and older and is not included in the current recommendation. However, [Moderna has filed](#) for an expanded indication in 18 – 59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD) with approval expected in June 2025. If FDA approval is received, Moderna's mRESVIA will be added to the current recommendation.
- The recommendation was based on the following:
 - According to the CDC, an estimated [15,000 – 20,000 annual RSV-associated hospitalizations](#) occur in the U.S. in adults aged 50 to 59.
 - A review of positive results of a phase 3 trial evaluating the immune response and safety of Arexvy in adults ages 50 - 59, including those at increased risk for severe RSV-LRTD due to certain underlying medical conditions, compared to adults aged 60 and above.
 - Adults aged 50 – 59 years who are hospitalized with RSV have similar underlying conditions as those in hospitalized adults ≥ 60 years.

What's next:

- The new recommendations from ACIP are pending approval from the director of the CDC and the Department of Health and Human Services (HHS).
- When approved and final, updated recommendations for RSV vaccines may be found [here](#).